Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ESMO open

Showing results (101-110 of 2,246) with videos related to

Pageof 225
Sort By:
ESMO Open|November 16, 2016
Highlights for ESMO 40: celebration review for lifetime achievement awardsNagahiro Saijo
ESMO Open|November 16, 2016
Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trialY Kurokawa, N Boku, T Yamaguchi, et al.
ESMO Open|November 16, 2016
Drug development: successes, problems and pitfalls-the industry perspectiveWolfgang Wein
ESMO Open|November 16, 2016
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancersAnna S Berghoff, Sophie Schur, Lisa M Füreder, et al.
ESMO Open|November 16, 2016
Quality of life during first-line FOLFOX4±panitumumab in <i>RAS</i> wild-type metastatic colorectal carcinoma: results from a randomised controlled trialSalvatore Siena, Josep Tabernero, Gyorgy Bodoky, et al.
ESMO Open|November 16, 2016
In the literature: March 2016A Cervantes
ESMO Open|November 16, 2016
Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an exampleStine Braendegaard Winther, Trine Lembrecht Jørgensen, Per Pfeiffer, et al.
ESMO Open|November 16, 2016
Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical OncologyYasuo Hirayama, Jiichiro Sasaki, Hirotoshi Dosaka-Akita, et al.
ESMO Open|November 16, 2016
ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO AwardNathan I Cherny
ESMO Open|November 16, 2016
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsJordi Remon, Benjamin Besse
Pageof 225

Showing results (101-110 of 2,246) with videos related to

Sort By:
Pageof 225
ESMO Open|November 16, 2016
Highlights for ESMO 40: celebration review for lifetime achievement awardsNagahiro Saijo
ESMO Open|November 16, 2016
Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trialY Kurokawa, N Boku, T Yamaguchi, et al.
ESMO Open|November 16, 2016
Drug development: successes, problems and pitfalls-the industry perspectiveWolfgang Wein
ESMO Open|November 16, 2016
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancersAnna S Berghoff, Sophie Schur, Lisa M Füreder, et al.
ESMO Open|November 16, 2016
Quality of life during first-line FOLFOX4±panitumumab in <i>RAS</i> wild-type metastatic colorectal carcinoma: results from a randomised controlled trialSalvatore Siena, Josep Tabernero, Gyorgy Bodoky, et al.
ESMO Open|November 16, 2016
In the literature: March 2016A Cervantes
ESMO Open|November 16, 2016
Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an exampleStine Braendegaard Winther, Trine Lembrecht Jørgensen, Per Pfeiffer, et al.
ESMO Open|November 16, 2016
Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical OncologyYasuo Hirayama, Jiichiro Sasaki, Hirotoshi Dosaka-Akita, et al.
ESMO Open|November 16, 2016
ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO AwardNathan I Cherny
ESMO Open|November 16, 2016
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsJordi Remon, Benjamin Besse
Pageof 225